Home Newsfeeds Redburn Partners Initiates Coverage On Sabre with Buy Rating

Redburn Partners Initiates Coverage On Sabre with Buy Rating

Redburn Partners analyst James Goodall initiates coverage on Sabre (NASDAQ:SABR) with a Buy rating.

byBenzinga Newsdesk

September 28, 2022

1 minute read

Redburn Partners analyst James Goodall initiates coverage on Sabre (NASDAQ:SABR) with a Buy rating.

Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

December 29, 9:51 AM

Shares of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) rose sharply in today’s pre-market trading session. Titan Pharmaceuticals said its Board of Directors has approved a 1-for-20 reverse stock split. Titan Pharmaceuticals shares jumped 15.2% to $0.38 in pre-market trading.

ASST

Mizuho Maintains Underperform on Vornado Realty, Lowers Price Target to $25

By Benzinga Newsdesk

October 19, 7:58 AM

Mizuho analyst Vikram Malhotra maintains Vornado Realty (NYSE:VNO) with a Underperform and lowers the price target from $30 to $25.

VNO

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

By Vandana Singh

December 15, 2:49 PM

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension

GKOS

BMO Capital Maintains Market Perform on UiPath, Lowers Price Target to $15

By Benzinga Newsdesk

September 7, 8:56 AM

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:PATH) with a Market Perform and lowers the price target from $21 to $15.

PATH

Redburn Partners Initiates Coverage On Sabre with Buy Rating

Related Posts

Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Mizuho Maintains Underperform on Vornado Realty, Lowers Price Target to $25

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

BMO Capital Maintains Market Perform on UiPath, Lowers Price Target to $15